Related Experiment Video
Updated: Jan 16, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
Prelamin A Does Not Promote Atherosclerosis or Vascular Smooth Muscle Loss
Insights
Full-length prelamin A does not promote atherosclerosis or vascular smooth muscle loss. This finding contrasts with progerin in Hutchinson-Gilford progeria syndrome (HGPS), suggesting prelamin A is not a driver of vascular aging.
Area of Science:
- Cardiovascular Biology
- Aging Research
- Molecular Genetics
Background:
- Hutchinson-Gilford progeria syndrome (HGPS) involves mutations in LMNA, leading to progerin production and vascular smooth muscle cell (VSMC) loss.
- Accumulation of full-length farnesylated prelamin A may contribute to vascular pathology in physiological aging.
Purpose of the Study:
- To investigate the impact of prelamin A accumulation on atherosclerosis and VSMCs.
- To determine if prelamin A expression drives vascular aging.
Main Methods:
- Utilized Lmna L648R/L648R mice expressing a prelamin A variant that cannot be processed to mature lamin A.
- Crossed these mice with Ldlr-/- mice to induce hyperlipidemia and atherosclerosis on a high-fat diet.
Main Results:
- No significant differences in atherosclerotic plaque or necrotic core areas were observed between mice expressing only prelamin A and those expressing only mature lamin A.
- Exclusive prelamin A expression did not cause VSMC loss or adventitial thickening in hyperlipidemic mice with atherosclerosis.
- Aortic vascular smooth muscle remained normal in aged Lmna L648R/L648R mice.
Conclusions:
- Prelamin A does not appear to induce vascular smooth muscle loss.
- Prelamin A accumulation does not promote atherosclerosis or drive vascular aging.
- These findings differentiate prelamin A's role from the progerin variant in HGPS-related vascular pathology.
Background:
Hutchinson-Gilford progeria syndrome (HGPS) is an accelerated aging disorder characterized by numerous symptoms, including early-onset atherosclerosis, with most patients suffering fatal myocardial infarctions or strokes by the second decade of life. HGPS is caused by mutations in LMNA that lead to expression of an internally truncated, farnesylated prelamin A variant called progerin, which induces loss of vascular smooth muscle cells (VSMCs). Some studies have also reported that accumulation of full-length farnesylated prelamin A, which is normally completely processed to mature non-farnesylated lamin A, can also drive vascular pathology during physiological aging.
Methods:
To assess the effects of prelamin A expression on atherosclerosis and aortic VSMCs, we used Lmna L648R/L648R mice that express a prelamin A variant with a lysine to arginine point mutation that prevents its processing to mature lamin A. To determine if prelamin A expression has an impact on atherosclerotic plaques, we crossed Lmna L648R/L648R mice to LDL receptor-deficient Ldlr -/- mice that develop hyperlipidemia on a high-fat diet.
Results:
Atherosclerotic plaque lesion area and necrotic core area were not different in hyperlipidemic Lmna L648R/L648R mice that expressed only prelamin A, and no mature lamin A, compared to hyperlipidemic Lmna +/+ mice that expressed only fully-processed mature lamin A and no prelamin A. Additionally, exclusive prelamin A expression did not result in loss of aortic VSMCs or adventitial thickening in hyperlipidemic Lmna L648R/L648R mice with atherosclerosis at 28 weeks of age. Indeed, aortic vascular smooth muscle remained normal in older Lmna L648R/L648R mice at 52 weeks of age.
Conclusions:
In contrast to the prelamin A variant progerin expressed in HGPS, prelamin A does not appear to cause vascular smooth muscle loss, promote atherosclerosis or drive vascular aging.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Inflammation
Atherosclerosis IV: Nursing Management
Antihypertensive Drugs: Action of Calcium Channel Blockers
Peripheral Artery Disease I: Introduction

